CA2446723C - Antibodies that immunospecifically bind to trail receptors - Google Patents
Antibodies that immunospecifically bind to trail receptors Download PDFInfo
- Publication number
- CA2446723C CA2446723C CA2446723A CA2446723A CA2446723C CA 2446723 C CA2446723 C CA 2446723C CA 2446723 A CA2446723 A CA 2446723A CA 2446723 A CA2446723 A CA 2446723A CA 2446723 C CA2446723 C CA 2446723C
- Authority
- CA
- Canada
- Prior art keywords
- replaced
- antibody
- fragment
- amino acid
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 title abstract description 21
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 title abstract description 18
- 239000012634 fragment Substances 0.000 claims abstract description 162
- 238000000034 method Methods 0.000 claims abstract description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 241000282414 Homo sapiens Species 0.000 claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 208000035475 disorder Diseases 0.000 claims abstract description 16
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 241001465754 Metazoa Species 0.000 claims abstract description 11
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 405
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 392
- 229920001184 polypeptide Polymers 0.000 claims description 371
- 108090000623 proteins and genes Proteins 0.000 claims description 136
- 102000004169 proteins and genes Human genes 0.000 claims description 130
- 125000000539 amino acid group Chemical group 0.000 claims description 124
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 91
- 108060003951 Immunoglobulin Proteins 0.000 claims description 19
- 230000006907 apoptotic process Effects 0.000 claims description 19
- 102000018358 immunoglobulin Human genes 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 15
- -1 166Ho Chemical compound 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 238000010494 dissociation reaction Methods 0.000 claims description 3
- 230000005593 dissociations Effects 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 241000237519 Bivalvia Species 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000020639 clam Nutrition 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 231100000334 hepatotoxic Toxicity 0.000 claims 1
- 230000003082 hepatotoxic effect Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 abstract description 24
- 102000039446 nucleic acids Human genes 0.000 abstract description 22
- 108020004707 nucleic acids Proteins 0.000 abstract description 22
- 201000010099 disease Diseases 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 8
- 230000002062 proliferating effect Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 3
- 239000013598 vector Substances 0.000 abstract description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 464
- 229910052721 tungsten Inorganic materials 0.000 description 458
- 229910052731 fluorine Inorganic materials 0.000 description 456
- 229910052727 yttrium Inorganic materials 0.000 description 446
- 229910052739 hydrogen Inorganic materials 0.000 description 438
- 229910052698 phosphorus Inorganic materials 0.000 description 411
- 229910052700 potassium Inorganic materials 0.000 description 408
- 229910052720 vanadium Inorganic materials 0.000 description 185
- 229910052757 nitrogen Inorganic materials 0.000 description 138
- 235000018102 proteins Nutrition 0.000 description 129
- KCUNTYMNJVXYKZ-JTQLQIEISA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-JTQLQIEISA-N 0.000 description 102
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 91
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 77
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 76
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 64
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 64
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 56
- 235000001014 amino acid Nutrition 0.000 description 55
- 108020001507 fusion proteins Proteins 0.000 description 49
- 102000037865 fusion proteins Human genes 0.000 description 49
- 229940024606 amino acid Drugs 0.000 description 46
- 150000001413 amino acids Chemical class 0.000 description 46
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 43
- 229910052740 iodine Inorganic materials 0.000 description 42
- 229910052717 sulfur Inorganic materials 0.000 description 42
- 102000005962 receptors Human genes 0.000 description 39
- 108020003175 receptors Proteins 0.000 description 39
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 37
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 33
- 230000000890 antigenic effect Effects 0.000 description 31
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 28
- 238000012217 deletion Methods 0.000 description 28
- 230000037430 deletion Effects 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 26
- 239000003446 ligand Substances 0.000 description 23
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 22
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 22
- 230000027455 binding Effects 0.000 description 20
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 19
- 238000009739 binding Methods 0.000 description 19
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 19
- 235000018417 cysteine Nutrition 0.000 description 19
- 230000002163 immunogen Effects 0.000 description 19
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 230000004071 biological effect Effects 0.000 description 16
- 125000005647 linker group Chemical group 0.000 description 16
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 16
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 14
- 102000003390 tumor necrosis factor Human genes 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 102000010170 Death domains Human genes 0.000 description 12
- 108050001718 Death domains Proteins 0.000 description 12
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 12
- 210000004899 c-terminal region Anatomy 0.000 description 11
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 10
- 239000000178 monomer Substances 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 230000000717 retained effect Effects 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 230000008827 biological function Effects 0.000 description 8
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000000710 homodimer Substances 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
- 230000005714 functional activity Effects 0.000 description 7
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 6
- 239000004233 Indanthrene blue RS Substances 0.000 description 6
- 239000004333 gold (food color) Substances 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 239000004175 ponceau 4R Substances 0.000 description 6
- 239000004293 potassium hydrogen sulphite Substances 0.000 description 6
- 239000004302 potassium sorbate Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000004332 silver Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000004308 thiabendazole Substances 0.000 description 6
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 5
- 101150064015 FAS gene Proteins 0.000 description 5
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 5
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 5
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 5
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 4
- 239000004254 Ammonium phosphate Substances 0.000 description 4
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 4
- 239000001698 Lecitin citrate Substances 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000004936 P-84 Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 4
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 101150009046 Tnfrsf1a gene Proteins 0.000 description 4
- 239000001809 ammonium phosphatide Substances 0.000 description 4
- 230000031018 biological processes and functions Effects 0.000 description 4
- 239000001354 calcium citrate Substances 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 239000000555 dodecyl gallate Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000004320 sodium erythorbate Substances 0.000 description 4
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 4
- 239000013638 trimer Substances 0.000 description 4
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 3
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 3
- 108010021466 Mutant Proteins Proteins 0.000 description 3
- 102000008300 Mutant Proteins Human genes 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 108091007178 TNFRSF10A Proteins 0.000 description 3
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 3
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 3
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 3
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229960000303 topotecan Drugs 0.000 description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- 239000002656 Distearyl thiodipropionate Substances 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 108010008177 Fd immunoglobulins Proteins 0.000 description 2
- 208000001204 Hashimoto Disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108010054862 Member 10c Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 101100484930 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) VPS41 gene Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000004178 amaranth Substances 0.000 description 2
- 239000000728 ammonium alginate Substances 0.000 description 2
- 230000009830 antibody antigen interaction Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000004126 brilliant black BN Substances 0.000 description 2
- 239000011692 calcium ascorbate Substances 0.000 description 2
- 235000010376 calcium ascorbate Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000004121 copper complexes of chlorophylls and chlorophyllins Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 108010052621 fas Receptor Proteins 0.000 description 2
- 102000018823 fas Receptor Human genes 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000004337 magnesium citrate Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001521 potassium lactate Substances 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- KUHSEZKIEJYEHN-BXRBKJIMSA-N (2s)-2-amino-3-hydroxypropanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.OC[C@H](N)C(O)=O KUHSEZKIEJYEHN-BXRBKJIMSA-N 0.000 description 1
- PSLCKQYQNVNTQI-BHFSHLQUSA-N (2s)-2-aminobutanedioic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O PSLCKQYQNVNTQI-BHFSHLQUSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 102000002627 4-1BB Ligand Human genes 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108010046080 CD27 Ligand Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 101100015199 Caenorhabditis elegans gly-11 gene Proteins 0.000 description 1
- 101100291031 Caenorhabditis elegans gly-13 gene Proteins 0.000 description 1
- 101100228200 Caenorhabditis elegans gly-5 gene Proteins 0.000 description 1
- 102000004091 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- SNPQGCDJHZAVOB-SOMABOLJSA-N D-glucosyl-N-tetracosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCC)COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SNPQGCDJHZAVOB-SOMABOLJSA-N 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 108010077716 Fas-Associated Death Domain Protein Proteins 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 230000010556 Heparin Binding Activity Effects 0.000 description 1
- 206010019972 Herpes viral infections Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100425758 Mus musculus Tnfrsf1b gene Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091008604 NGF receptors Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000004218 Orcein Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004236 Ponceau SX Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100028644 Tenascin-R Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000004294 calcium hydrogen sulphite Substances 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 101150055276 ced-3 gene Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000002873 global sequence alignment Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Substances [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108010020387 tenascin R Proteins 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29347301P | 2001-05-25 | 2001-05-25 | |
| US60/293,473 | 2001-05-25 | ||
| US29498101P | 2001-06-04 | 2001-06-04 | |
| US60/294,981 | 2001-06-04 | ||
| US30917601P | 2001-08-02 | 2001-08-02 | |
| US60/309,176 | 2001-08-02 | ||
| US32380701P | 2001-09-21 | 2001-09-21 | |
| US60/323,807 | 2001-09-21 | ||
| US32736401P | 2001-10-09 | 2001-10-09 | |
| US60/327,364 | 2001-10-09 | ||
| US33104401P | 2001-11-07 | 2001-11-07 | |
| US60/331,044 | 2001-11-07 | ||
| US33131001P | 2001-11-14 | 2001-11-14 | |
| US60/331,310 | 2001-11-14 | ||
| US34123701P | 2001-12-20 | 2001-12-20 | |
| US60/341,237 | 2001-12-20 | ||
| US36986002P | 2002-04-05 | 2002-04-05 | |
| US60/369,860 | 2002-04-05 | ||
| PCT/US2002/014268 WO2002097033A2 (en) | 2001-05-25 | 2002-05-07 | Antibodies that immunospecifically bind to trail receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2446723A1 CA2446723A1 (en) | 2002-12-05 |
| CA2446723C true CA2446723C (en) | 2014-01-21 |
Family
ID=50151047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2446723A Expired - Lifetime CA2446723C (en) | 2001-05-25 | 2002-05-07 | Antibodies that immunospecifically bind to trail receptors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7064189B2 (enExample) |
| EP (1) | EP1572874B1 (enExample) |
| JP (2) | JP4309758B2 (enExample) |
| KR (1) | KR100942393B1 (enExample) |
| CN (1) | CN100594935C (enExample) |
| AU (1) | AU2002309647C1 (enExample) |
| CA (1) | CA2446723C (enExample) |
| DK (1) | DK1572874T3 (enExample) |
| ES (1) | ES2437992T3 (enExample) |
| MX (1) | MXPA03010747A (enExample) |
| NZ (1) | NZ529359A (enExample) |
| PT (1) | PT1572874E (enExample) |
| WO (1) | WO2002097033A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002211658A1 (en) * | 2000-10-13 | 2002-04-22 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| US20060062786A1 (en) * | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US20050129616A1 (en) * | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| WO2004016753A2 (en) * | 2002-08-15 | 2004-02-26 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| US7361341B2 (en) * | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| CA2446723C (en) * | 2001-05-25 | 2014-01-21 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US20050214209A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| WO2003066661A2 (en) | 2001-07-03 | 2003-08-14 | Genentech, Inc. | Human dr4 antibodies and uses thereof |
| CN1610696A (zh) * | 2001-12-20 | 2005-04-27 | 人体基因组科学有限公司 | 免疫特异性结合trail受体的抗体 |
| US20060083738A1 (en) * | 2002-05-17 | 2006-04-20 | Fusion Antibodies Limited | Treatment of cancer by the use of anti fas antibody |
| JP2004279086A (ja) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | 放射線画像変換パネル及び放射線画像変換パネルの製造方法 |
| PL1606318T3 (pl) * | 2003-03-26 | 2010-01-29 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Ulepszone białka fuzyjne FC |
| EP1619498B1 (en) * | 2003-04-16 | 2011-01-05 | Ono Pharmaceutical Co., Ltd. | Method of screening remedy for heart disease and medicinal composition for treating heart disease |
| EP1633316A4 (en) * | 2003-05-06 | 2008-04-02 | Human Genome Sciences Inc | ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS |
| US20080206229A1 (en) * | 2003-12-12 | 2008-08-28 | Koichiro Ono | Modified Antibodies Recognizing Receptor Trimers or Higher Multimers |
| US20060018911A1 (en) * | 2004-01-12 | 2006-01-26 | Dana Ault-Riche | Design of therapeutics and therapeutics |
| WO2006017859A2 (en) | 2004-08-06 | 2006-02-16 | Genentech, Inc. | Assays and methods using biomarkers |
| MX2007001469A (es) | 2004-08-06 | 2007-03-26 | Genentech Inc | Ensayos y metodos que utilizan biomarcadores. |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| EP1870458B1 (en) | 2005-03-31 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2 STRUCTURAL ISOMERS |
| WO2006132363A1 (ja) | 2005-06-10 | 2006-12-14 | Chugai Seiyaku Kabushiki Kaisha | メグルミンを含有するタンパク質製剤の安定化剤、およびその利用 |
| CN101262885B (zh) | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
| AU2006279618A1 (en) | 2005-08-16 | 2007-02-22 | Genentech, Inc. | Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues |
| US20080305512A1 (en) * | 2006-10-26 | 2008-12-11 | Mattingly Phillip G | Assay for cardiac troponin autoantibodies |
| CA2667012A1 (en) * | 2006-10-26 | 2008-05-02 | Abbott Laboratories | Immunoassay of analytes in samples containing endogenous anti-analyte antibodies |
| US7776605B2 (en) * | 2006-10-26 | 2010-08-17 | Abbott Laboratories | Assay for cardiac troponin autoantibodies |
| JP2012522492A (ja) * | 2009-04-03 | 2012-09-27 | インスティテュート オブ ベーシック メディカル サイエンシズ チャイニーズ アカデミー オブ メディカル サイエンシズ | 抗ヒトデスレセプターｄｒ５モノクローナル抗体ａｄ５−１０により認識される抗原決定基、その誘導体およびその使用 |
| WO2011043835A1 (en) * | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Polypeptides that bind il-23r |
| EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| LT2970473T (lt) | 2013-03-14 | 2017-10-25 | Bristol-Myers Squibb Company | Dr5 agonisto ir anti-pd-1 antagonisto derinys ir naudojimo būdai |
| EP3218405A4 (en) * | 2014-11-14 | 2018-09-12 | Beijing Cotimes Biotech Co., Ltd. | Trail receptor-binding agents and uses of same |
| AU2016363770A1 (en) | 2015-12-01 | 2018-06-28 | Genmab B.V. | Anti-DR5 antibodies and methods of use thereof |
| US12422440B2 (en) | 2018-10-05 | 2025-09-23 | Seattle Children's Hospital | Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease |
| EP4388013A4 (en) * | 2021-08-20 | 2025-12-24 | Univ Virginia Patent Foundation | A HIGHLY SUPERIOR DR5 ACTIVATION STRATEGY, PARTICULARLY IN TUMORS AND CANCERS |
Family Cites Families (172)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496654A (en) * | 1983-04-08 | 1985-01-29 | Quidel | Detection of HCG with solid phase support having avidin coating |
| JPS60150456A (ja) | 1984-01-19 | 1985-08-08 | Diesel Kiki Co Ltd | 内燃機関用燃料噴射装置 |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
| US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
| NZ229700A (en) | 1988-06-24 | 1993-01-27 | Dow Chemical Co | Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragments |
| US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| GB8924021D0 (en) | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| FI90454C (fi) | 1990-02-22 | 1994-02-10 | Patenttitoimisto T Poutanen Oy | Menetelmä naulalevykattotuolin valmistamiseksi |
| JP3319594B2 (ja) | 1990-03-20 | 2002-09-03 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体 |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| ES2120949T4 (es) | 1990-06-28 | 2011-12-29 | Sanofi-Aventis Deutschland Gmbh 50% | Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE4025687A1 (de) | 1990-08-14 | 1992-02-20 | Ruetgerswerke Ag | Durch strahlung vernetzbare bindemittelgemische |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| KR100246529B1 (ko) | 1990-12-14 | 2000-04-01 | 스티븐 에이. 서윈. 엠.디. | 수용체 관련된 신호 변환 경로를 위한 키메라 사슬 |
| US5714711A (en) | 1990-12-31 | 1998-02-03 | Mei Corporation | Encapsulated propellant grain composition, method of preparation, article fabricated therefrom and method of fabrication |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE69233441T2 (de) | 1991-04-26 | 2005-10-13 | Osaka Bioscience Institute, Suita | Menschliches Zelloberflächen-Antigen codierende DNA |
| EP0584279B1 (en) | 1991-05-14 | 2001-03-14 | The University Of Connecticut | Targeted delivery of genes encoding immunogenic proteins |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE4119353C1 (enExample) | 1991-06-12 | 1992-12-17 | Deutsche Rockwool Mineralwoll Gmbh, 4390 Gladbeck, De | |
| US5356603A (en) | 1991-06-17 | 1994-10-18 | Johnson Matthey Inc. | Method for the production of hydrocyanic acid using a corrugated catalyst |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| CA2133411A1 (en) | 1992-04-03 | 1993-10-14 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| GB9214857D0 (en) | 1992-07-13 | 1992-08-26 | Medical Res Council | Human nucleic acid fragments and their use |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE4233586A1 (de) | 1992-10-06 | 1994-04-07 | Bayer Ag | 3-Imino-3-alkoxy-propionsäurelactate und deren tautomere Acrylsäurelactate |
| ATE200625T1 (de) | 1992-10-09 | 2001-05-15 | Advanced Tissue Sciences Inc | Leberreservezellen |
| CA2146559A1 (en) | 1992-10-23 | 1994-05-11 | Melanie K. Spriggs | Methods of preparing soluble, oligomeric proteins |
| CA2145641C (en) | 1992-12-03 | 2008-05-27 | Richard J. Gregory | Pseudo-adenovirus vectors |
| US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5620889A (en) | 1993-10-14 | 1997-04-15 | Immunex Corporation | Human anti-Fas IgG1 monoclonal antibodies |
| US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| JP2552425B2 (ja) | 1993-12-14 | 1996-11-13 | コナミ株式会社 | 実況中継機能付きゲーム機 |
| PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5985660A (en) | 1994-06-15 | 1999-11-16 | Systemix, Inc. | Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation |
| JPH10503371A (ja) | 1994-07-29 | 1998-03-31 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 新規化合物 |
| KR100507431B1 (ko) | 1994-11-07 | 2005-12-21 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 종양괴사인자-γ |
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| JP3521016B2 (ja) | 1995-03-27 | 2004-04-19 | 松下電器産業株式会社 | 直交周波数分割多重信号の受信方法および受信装置 |
| US5516717A (en) | 1995-04-19 | 1996-05-14 | United Microelectronics Corporation | Method for manufacturing electrostatic discharge devices |
| EP2017337A1 (en) | 1995-04-27 | 2009-01-21 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptors |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU5919096A (en) | 1995-05-08 | 1996-11-29 | Michel J. Hourani | Alkoxylated dimethylolpropionic acid modifier |
| DE19523218A1 (de) | 1995-06-27 | 1997-01-02 | Schaeffler Waelzlager Kg | Hydraulisch betätigte Ausrückvorrichtung für eine Reibungskupplung |
| EP1666591B1 (en) * | 1995-06-29 | 2011-03-23 | Immunex Corporation | Cytokine that induces apoptosis |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| WO1997034911A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
| DE19611367A1 (de) | 1996-03-22 | 1997-09-25 | Bayer Ag | Verfahren zur Herstellung Kohlenwasserstoff-getriebener Polyurethan-Hartschaumstoffe |
| DE69722603T2 (de) | 1996-03-27 | 2004-05-13 | Novartis Ag | Verfahren zur herstellung von eines poröses polymer aus einer mischung |
| EP1947183B1 (en) | 1996-08-16 | 2013-07-17 | Merck Sharp & Dohme Corp. | Mammalian cell surface antigens; related reagents |
| JP2000516474A (ja) | 1996-08-16 | 2000-12-12 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | ヒトエンドカインα |
| JPH1057071A (ja) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | 新規ｄｎａ及びそれを用いた蛋白質の製造方法 |
| EP0961832A4 (en) | 1996-09-18 | 2003-02-26 | Human Genome Sciences Inc | HUMAN TUMOR NECROSIS FACTOR-TYPE RECEPTOR GENES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2266439C (en) | 1996-10-25 | 2009-06-16 | Human Genome Sciences, Inc. | Neutrokine .alpha. |
| EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| WO1998030693A2 (en) | 1997-01-14 | 1998-07-16 | Human Genome Sciences, Inc. | Tumor necrosis factor receptor 5 |
| ATE365796T1 (de) | 1997-01-14 | 2007-07-15 | Human Genome Sciences Inc | Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta |
| EP0857782A3 (en) | 1997-01-27 | 1999-12-22 | Smithkline Beecham Corporation | Novel mammalian DD-1 gene |
| EP1012274B2 (en) * | 1997-01-28 | 2011-06-15 | Human Genome Sciences, Inc. | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l) |
| US6433147B1 (en) * | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| DE69800640T2 (de) | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc, London | Pegylationsverfahren |
| CA2221687A1 (en) | 1997-02-05 | 1998-08-05 | Smithkline Beecham Corporation | Tumor necrosis related receptor, tr5 |
| US6072047A (en) | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US6313269B1 (en) * | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
| US20010010924A1 (en) | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| ATE352618T1 (de) | 1997-03-17 | 2007-02-15 | Human Genome Sciences Inc | Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält |
| US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| SI0970126T1 (en) | 1997-04-14 | 2001-08-31 | Micromet Ag | Novel method for the production of antihuman antigen receptors and uses thereof |
| AU7126498A (en) | 1997-04-16 | 1998-11-11 | Millennium Pharmaceuticals, Inc. | Tumor necrosis factor receptor related proteins tango-63d and tango-63e |
| WO1998049305A1 (en) | 1997-05-01 | 1998-11-05 | Amgen Inc. | Chimeric opg polypeptides |
| EP0975674B1 (en) | 1997-05-02 | 2005-08-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Immunotoxins, comprising an onc protein, directed against malignant cells |
| ES2293682T5 (es) * | 1997-05-15 | 2011-11-17 | Genentech, Inc. | Anticuerpo anti-apo2. |
| US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| US6214580B1 (en) | 1997-05-30 | 2001-04-10 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor tr10 |
| CA2295991A1 (en) | 1997-06-11 | 1998-12-17 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor tr9 |
| EP1032661A1 (en) | 1997-06-18 | 2000-09-06 | Genentech, Inc. | Apo-2DcR |
| EP1001990A4 (en) | 1997-06-26 | 2001-12-19 | Immunex Corp | PROTEIN BINDING TO TRAIL PROTEIN |
| WO1999002653A1 (en) | 1997-07-11 | 1999-01-21 | Trustees Of The University Of Pennsylvania | Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use |
| JP2001510042A (ja) | 1997-07-15 | 2001-07-31 | イミュネックス・コーポレーション | Ｔｒａｉｌ受容体 |
| JP2001514888A (ja) | 1997-08-15 | 2001-09-18 | アイドゥン ファーマシューティカルズ， インコーポレイテッド | Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法 |
| CA2301847A1 (en) | 1997-08-26 | 1999-03-04 | Genentech, Inc. | Rtd receptor |
| WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| DE69837606T2 (de) | 1997-09-12 | 2008-02-14 | Biogen Idec Ma Inc., Cambridge | Cystein-reiche rezeptoren-train |
| ATE384732T1 (de) | 1997-11-03 | 2008-02-15 | Human Genome Sciences Inc | Vegi, ein inhibitor der angiogenese und des tumorwachstums |
| JP2002500877A (ja) * | 1998-01-26 | 2002-01-15 | ジェネンテク・インコーポレイテッド | 細胞死レセプター４（ｄｒ４）に対する抗体及びその使用 |
| US6790823B1 (en) | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| WO2000008155A2 (en) | 1998-08-07 | 2000-02-17 | Incyte Pharmaceuticals, Inc. | Human receptor-associated proteins |
| AU6006099A (en) | 1998-10-09 | 2000-05-01 | Sankyo Company Limited | Preventives or remedies for cachexia |
| DE19856878A1 (de) | 1998-12-10 | 2000-06-15 | Inst Polymerforschung Dresden | Härtbare uretdiongruppenhaltige Massen und ein Verfahren zu ihrer Herstellung und Verarbeitung sowie ihre Verwendung |
| CA2363112A1 (en) | 1999-02-23 | 2000-08-31 | Craig A. Rosen | Neutrokine-alpha and neutrokine-alpha splice variant |
| WO2000054651A2 (en) | 1999-03-15 | 2000-09-21 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like genes |
| CA2369371A1 (en) | 1999-05-04 | 2000-11-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| CA2373063A1 (en) | 1999-05-06 | 2000-11-16 | Jian Ni | Death domain containing receptor 4 |
| CA2374674A1 (en) | 1999-05-20 | 2000-11-30 | Human Genome Sciences, Inc. | Tumor necrosis factor receptor 5 |
| CA2372246A1 (en) | 1999-05-28 | 2000-12-07 | Craig A. Rosen | Human tumor necrosis factor receptor tr10 |
| PT1181319E (pt) | 1999-05-28 | 2009-07-14 | Genentech Inc | Anticorpos quiméricos contra dr4 e suas utilizações |
| IL146491A0 (en) | 1999-06-09 | 2002-07-25 | Genentech Inc | APo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM |
| AU6343400A (en) | 1999-07-09 | 2001-01-30 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene |
| WO2001003719A2 (en) | 1999-07-09 | 2001-01-18 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| DK1294769T3 (da) * | 2000-06-16 | 2011-04-26 | Human Genome Sciences Inc | Antistoffer der immunspecifikt binder til BLyS |
| CA2446723C (en) * | 2001-05-25 | 2014-01-21 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
-
2002
- 2002-05-07 CA CA2446723A patent/CA2446723C/en not_active Expired - Lifetime
- 2002-05-07 WO PCT/US2002/014268 patent/WO2002097033A2/en not_active Ceased
- 2002-05-07 MX MXPA03010747A patent/MXPA03010747A/es active IP Right Grant
- 2002-05-07 DK DK02736661.6T patent/DK1572874T3/da active
- 2002-05-07 ES ES02736661.6T patent/ES2437992T3/es not_active Expired - Lifetime
- 2002-05-07 CN CN02814904A patent/CN100594935C/zh not_active Expired - Lifetime
- 2002-05-07 NZ NZ529359A patent/NZ529359A/en not_active IP Right Cessation
- 2002-05-07 PT PT27366616T patent/PT1572874E/pt unknown
- 2002-05-07 JP JP2003500202A patent/JP4309758B2/ja not_active Expired - Lifetime
- 2002-05-07 AU AU2002309647A patent/AU2002309647C1/en not_active Ceased
- 2002-05-07 KR KR1020037015417A patent/KR100942393B1/ko not_active Expired - Fee Related
- 2002-05-07 US US10/139,785 patent/US7064189B2/en not_active Expired - Lifetime
- 2002-05-07 EP EP02736661.6A patent/EP1572874B1/en not_active Expired - Lifetime
-
2008
- 2008-11-13 JP JP2008291575A patent/JP2009062393A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR100942393B1 (ko) | 2010-02-17 |
| ES2437992T3 (es) | 2014-01-15 |
| PT1572874E (pt) | 2013-12-11 |
| US20030190685A1 (en) | 2003-10-09 |
| AU2002309647C1 (en) | 2008-09-11 |
| EP1572874A2 (en) | 2005-09-14 |
| JP2005515963A (ja) | 2005-06-02 |
| WO2002097033A3 (en) | 2005-10-20 |
| EP1572874A4 (en) | 2006-05-31 |
| WO2002097033A2 (en) | 2002-12-05 |
| NZ529359A (en) | 2007-04-27 |
| MXPA03010747A (es) | 2004-03-02 |
| CA2446723A1 (en) | 2002-12-05 |
| AU2002309647B2 (en) | 2008-01-24 |
| EP1572874B1 (en) | 2013-09-18 |
| JP4309758B2 (ja) | 2009-08-05 |
| CN1635908A (zh) | 2005-07-06 |
| US7064189B2 (en) | 2006-06-20 |
| JP2009062393A (ja) | 2009-03-26 |
| KR20040003015A (ko) | 2004-01-07 |
| HK1075470A1 (en) | 2005-12-16 |
| DK1572874T3 (da) | 2013-12-16 |
| CN100594935C (zh) | 2010-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2446723C (en) | Antibodies that immunospecifically bind to trail receptors | |
| US7348003B2 (en) | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors | |
| US7361341B2 (en) | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors | |
| US20030180296A1 (en) | Antibodies that immunospecifically bind to trail receptors | |
| US20050129616A1 (en) | Antibodies that immunospecifically bind to TRAIL receptors | |
| US20050214209A1 (en) | Antibodies that immunospecifically bind to TRAIL receptors | |
| US20030228309A1 (en) | Antibodies that immunospecifically bind to TRAIL receptors | |
| US20050214210A1 (en) | Antibodies that immunospecifically bind to TRAIL receptors | |
| US20090226429A1 (en) | Antibodies That Immunospecifically Bind to TRAIL Receptors | |
| US20050214205A1 (en) | Antibodies that immunospecifically bind to TRAIL receptors | |
| US20050214207A1 (en) | Antibodies that immunospecifically bind toTRAIL receptors | |
| AU2002309647A1 (en) | Antibodies that immunospecifically bind to trail receptors | |
| US20050214208A1 (en) | Antibodies that immunospecifically bind to TRAIL receptors | |
| EP1633316A2 (en) | Antibodies that immunospecifically bind to trail receptors | |
| WO2004016753A2 (en) | Antibodies that immunospecifically bind to trail receptors | |
| WO2003042367A2 (en) | Antibodies that immunospecifically bind to trail receptors | |
| WO2002079377A2 (en) | Antibodies that immunospecifically bind to trail receptors | |
| US20050214206A1 (en) | Antibodies that immunospecifically bind to TRAIL receptors | |
| AU2008201237A1 (en) | Antibodies that Immunospecifically Bind to Trail Receptors | |
| HK1075470B (en) | Antibodies that immunospecifically bind to trail receptors | |
| MXPA04006042A (es) | Anticuerpos que se unen inmunoespecificamente a receptores de trail. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20220509 |